Safety considerations Researchers are monitoring for: Adverse events Potential safety signals Discontinuation rates Impacts on cardiovascular disease, heart failure, and sleep apnea Changes in blood pressure and HbA1c As with any emerging therapy, more data from Phase 3 trials will be needed to fully understand risk versus benefit
Our Vision Be an established, diverse and leading education charity for the independent FE, HE and training sectors Expand accreditation and consultancy activities in the UK and international markets
However, we can achieve more robust skin tightening with devices that are designed specifically for that purpose, namely, Sofwave, Ulthera, and Thermage
Cardiovascular and kidney outcomes GLP-1 medications offer meaningful heart and kidney protection
Funding This study was partially supported by Fundao Carlos Chagas Filho de Amparo Pesquisa do Estado do Rio de Janeiro (FAPERJ - E-26/201.289/2022), Brazil